Loading…
Chinese biotechnology company selling in-vitro diagnostic reagents; exact test-menu scope not fully confirmed.
Chinese biotechnology company selling in-vitro diagnostic reagents; exact test-menu scope not fully confirmed.
Moat: none
Headquarters: Beijing, China · Employees: 998
Size Beijing Strong Biotechnologies (300406.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.13B, the 2072nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.83 on 6 Nov 2026.
Performance Over six months the shares gained 1.0%, against -13.9% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue fell 4.1% over the last twelve months (peer median +13.7%); the operating margin is 35.9% (peer median 8.6%).
Valuation It trades at 18.2× forward earnings against a peer median of 20.9× (5th cheapest of 12).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.7 points above its cost of capital (6.3% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.37B | CN¥1.34B | CN¥1.65B | CN¥1.73B | CN¥1.50B |
| Revenue growth | — | -19% | -5% | +15% | — |
| Gross profit | CN¥1.12B | CN¥1.01B | CN¥1.23B | CN¥1.24B | CN¥1.07B |
| EBITDA | n/a | CN¥479M | CN¥705M | CN¥674M | CN¥555M |
| Net income | CN¥251M | CN¥190M | CN¥538M | CN¥524M | CN¥389M |
| Free cash flow | CN¥559M | CN¥526M | CN¥568M | CN¥442M | CN¥310M |
| Capital expenditure | CN¥21.5M | CN¥39.2M | CN¥67.6M | CN¥148M | CN¥96.5M |
| Total debt | CN¥1.10B | CN¥1.07B | CN¥1.18B | CN¥1.19B | CN¥1.12B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300406.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.5% | +1.2% | 7th highest of 21 |
| 6-month return | +1.0% | -13.9% | 7th highest of 20 |
| Distance from 52-week high | -20.1% | -35.4% | 4th highest of 21 |
| Revenue growth (TTM) | -4.1% | +13.7% | 4th lowest of 20 |
| Operating margin | 35.9% | 8.6% | 2nd highest of 20 |
| Forward P/E | 18.2× | 20.9× | 5th cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | 1.5% | 8.8% | 3rd least demanding of 11 |
| Growth delivered (Del g) | +9.9% | +8.7% | 5th highest of 11 |
| Hurdle (Req g minus delivered) | -8.3 pp | +0.4 pp | 2nd least demanding of 11 |
| ROIC minus cost of capital | +3.7 pp | -4.8 pp | 6th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 18.2× | 1.5% | +9.9% |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 33.7× | 10.0% | +8.8% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | n/a | n/a | n/a |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 36.0× | 19.1% | +21.5% |
| Amoy Diagnostics 300685.SZ | China | $1.10B | -14% | +7% | 34% | 20.9× | 6.5% | +10.3% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -3% | 15.0× | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 9% | n/a | 53.9% | +8.6% |
| Freenome FRNM | United States | $1.09B | n/a | n/a | n/a | n/a | n/a | n/a |
| SI-BONE SIBN | United States | $1.09B | +98% | +14% | -8% | n/a | n/a | n/a |
| PHC 6523.T | Japan | $1.09B | +36% | +3% | 7% | 7.9× | -2.3% | +3.6% |
| Tinavi Medical Technologies 688277.SS | China | $1.08B | -30% | -2% | -59% | n/a | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | n/a | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $1.08B | -14% | +22% | 12% | 55.2× | 12.4% | +12.9% |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | n/a | n/a | n/a |
| L&C BIO 290650.KS | South Korea | $1.07B | -17% | +53% | 17% | 213.2× | n/a | n/a |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 18.8× | 7.7% | -2.9% |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 5.8× | 5.2% | +3.6% |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | n/a | n/a | n/a |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.24B | -25% | -6% | 18% | 27.0× | 12.7% | -3.5% |
| CLASSYS 214150.KS | South Korea | $1.25B | -54% | +25% | 46% | 12.1× | -8.7% | +34.5% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.26B | +58% | -29% | -74% | n/a | n/a | n/a |